TME PHARM.CONF.IPO EO 1- (0N6A) - Total Assets
Based on the latest financial reports, TME PHARM.CONF.IPO EO 1- (0N6A) holds total assets worth €2.14 Million EUR (≈ $2.50 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TME PHARM.CONF.IPO EO 1- - Total Assets Trend (2021–2025)
This chart illustrates how TME PHARM.CONF.IPO EO 1-'s total assets have evolved over time, based on quarterly financial data. Also see market cap of TME PHARM.CONF.IPO EO 1- for the company's overall valuation and market capitalisation.
TME PHARM.CONF.IPO EO 1- - Asset Composition Analysis
Current Asset Composition (December 2025)
TME PHARM.CONF.IPO EO 1-'s total assets of €2.14 Million consist of 99.2% current assets and 0.8% non-current assets. Review TME PHARM.CONF.IPO EO 1- balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 94.1% |
| Accounts Receivable | €2.00K | 0.1% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.00K | 0.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how TME PHARM.CONF.IPO EO 1-'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 0N6A stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TME PHARM.CONF.IPO EO 1-'s current assets represent 99.2% of total assets in 2025, a decrease from 99.2% in 2021.
- Cash Position: Cash and equivalents constituted 94.1% of total assets in 2025, down from 96.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 0.2% of total assets.
TME PHARM.CONF.IPO EO 1- Competitors by Total Assets
Key competitors of TME PHARM.CONF.IPO EO 1- based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
TME PHARM.CONF.IPO EO 1- - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.57 | 1.88 | 2.11 |
| Quick Ratio | 0.57 | 1.88 | 2.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-1.60 Million | €1.57 Million | €1.52 Million |
TME PHARM.CONF.IPO EO 1- - Advanced Valuation Insights
This section examines the relationship between TME PHARM.CONF.IPO EO 1-'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.94 |
| Latest Market Cap to Assets Ratio | 4.88 |
| Asset Growth Rate (YoY) | -37.2% |
| Total Assets | €2.14 Million |
| Market Capitalization | $10.44 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values TME PHARM.CONF.IPO EO 1-'s assets at a significant premium (4.88x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: TME PHARM.CONF.IPO EO 1-'s assets decreased by 37.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for TME PHARM.CONF.IPO EO 1- (2021–2025)
The table below shows the annual total assets of TME PHARM.CONF.IPO EO 1- from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.14 Million ≈ $2.50 Million |
-37.20% |
| 2024-12-31 | €3.41 Million ≈ $3.98 Million |
+36.73% |
| 2023-12-31 | €2.49 Million ≈ $2.91 Million |
-52.47% |
| 2022-12-31 | €5.24 Million ≈ $6.13 Million |
-46.35% |
| 2021-12-31 | €9.77 Million ≈ $11.42 Million |
-- |
About TME PHARM.CONF.IPO EO 1-
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indicatio… Read more